Tuesday, March 26, 2013
John Embry: Cyprus, Massive Global Debt, Derivatives & The End Game
from King World News
Today John Embry told King World News that what is happening in Cyrpus is just a prelude to a more catastrophic day when the financial system grinds to a halt. He says the Cyprus disaster has frightened people all around the world and things will only get worse from here. Below is what Embry, who is chief investment strategist at Sprott Asset Management, had to say regarding this ongoing crisis:
Eric King: “In the aftermath of what they are saying is a deal in Cyprus, John, what are your thoughts?”
Embry: “We knew they would come back with another solution because they can’t afford for a country as small as Cyprus to bring down the whole euro construct. I think people recognize that Germany has a vested interest in keeping this thing afloat because their banking system is loaded with all of this peripheral country debt.
Continue Reading at KingWorldNews.com…
Please share this article
Today John Embry told King World News that what is happening in Cyrpus is just a prelude to a more catastrophic day when the financial system grinds to a halt. He says the Cyprus disaster has frightened people all around the world and things will only get worse from here. Below is what Embry, who is chief investment strategist at Sprott Asset Management, had to say regarding this ongoing crisis:
Eric King: “In the aftermath of what they are saying is a deal in Cyprus, John, what are your thoughts?”
Embry: “We knew they would come back with another solution because they can’t afford for a country as small as Cyprus to bring down the whole euro construct. I think people recognize that Germany has a vested interest in keeping this thing afloat because their banking system is loaded with all of this peripheral country debt.
Continue Reading at KingWorldNews.com…
Please share this article
VIVUS, Inc. (NASDAQ: VVUS)
VIVUS, Inc., a biopharmaceutical company, engages in developing and
commercializing therapies to address unmet needs in obesity, sleep
apnea, diabetes, and sexual health. The company offers Qsymia, a drug
for the treatment of obesity as an adjunct to a reduced-calorie diet and
increased physical activity for chronic weight management in adult
patients with an initial body mass index of 30 or greater, or 27 or
greater in the presence of at least one weight-related comorbidity, such
as hypertension, type 2 diabetes mellitus, or high cholesterol; and
STENDRA for the treatment of erectile dysfunction. It also completed
Phase II clinical studies of Qsymia for the treatment of obstructive
sleep apnea; and Qsymia for the treatment of type 2 diabetes. The
company has an agreement with Mitsubishi Tanabe Pharma Corporation for
the development and commercialization of avanafil, a PDE5 inhibitor
compound for the oral and local treatment of male and female sexual
dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in
Mountain View, California.
To analyze the company's stock for potential trading opportunities, please take a look at the 1-year chart of VVUS (VIVUS, Inc.) below with my added notations:
Similarly to yesterday's “Big Stock”, VVUS has been trending sideways for the last (5) months. As the stock has bounced along, it has formed a couple of key price levels to watch. The first is the $10 level (blue) that has already acted as support on several occasions. The other is the $12 level (red) that VVUS is currently pulling away from.
The Tale of the Tape: VVUS appears to be on its way back down to $10. A long position could be entered at the $10 support or on a break above the $12 resistance, with a stop placed below the level of entry. A short play could be made on a break below $10 or on a rally back up to $12.
Please share this article
To analyze the company's stock for potential trading opportunities, please take a look at the 1-year chart of VVUS (VIVUS, Inc.) below with my added notations:
Similarly to yesterday's “Big Stock”, VVUS has been trending sideways for the last (5) months. As the stock has bounced along, it has formed a couple of key price levels to watch. The first is the $10 level (blue) that has already acted as support on several occasions. The other is the $12 level (red) that VVUS is currently pulling away from.
The Tale of the Tape: VVUS appears to be on its way back down to $10. A long position could be entered at the $10 support or on a break above the $12 resistance, with a stop placed below the level of entry. A short play could be made on a break below $10 or on a rally back up to $12.
Please share this article
Weimar Hyperinflation 1923 vs USA Today
In a short but powerful documentary of 6 minutes, our friends at FutureMoneyTrends show the similarities between the hyperinflationary period in the Weymar Republic in 1923 / 1924, and the USA today. The similarities in the pre-hyperinflationary period appear to be striking! In a nutshell:
- The national debt had risen to a point where it could not realistically be paid back.
- The war had costed more than expected.
- There was a high unemployment.
- Products and services increased in price, while production decreased significantly.
- The government’s response was to provide liquidity to the banks and inflate the currency.
- The gold standard was left several years before.
The only thing keeping the dollar afloat is a military bravado that keeps countries of the world inclined to use the dollar has a reserve currency. If that changes along with increasing deficits and diminishing public support for military interventions, we may see German style hyperinflation in the United States of America.As soon as the world witnesses the loss of trust in the US dollar (the world reserve currency), the financial and monetary system will implode under its own weight. The sad truth is that our beloved leaders are kicking the can down the road for several years, arguing that nothing is going now.
Please share this article
Dutch Finance Minister Loves Raiding Savings Accounts
traderdannorcini.blogspot.com / By Dan Norcini /
Reuters is reporting this morning comments from the Dutch Finance Minister, Jeroen Dijsselbloem, who by the way heads up the group of European Finance Ministers, to the effect that the “solution” in Cypress is a “new template” to address future banking problems in the Euro area.
I want you readers, particularly those of you in the Eurozone, to wrap your heads around this and consider the brazen audacity displayed by these people. What he is saying is that bank savings deposits no longer effectively belong to you the savers. They belong to the state and the state will confiscate them whenever it is deemed to be in that state’s best interests.
If this does not send shock waves throughout the system and instill fear in individuals throughout the Eurozone, then there is no hope for any such people. Normal, rational, sane, thinking individuals will immediately recognize this for what it is; a complete reversal of the traditional role of banking in which banks makes loans to depositors and other individuals. Now, depositors are in effect making loans to banks. Yet even that is not an apt comparison for in the case of a loan, one usually expects to receive back the amount loaned plus interest. In this case, the depositors are having their money forcibly extracted from them with no hope of ever seeing it again and having that money used to bail out the banks instead! I never believed I would EVER witness this in my life and yet here it is. What is even worse is the blasé attitude displayed by the monetary authorities. Just who in the hell do these people think that they are?
READ MORE
Chart of the Day - Seattle Genetics(SGEN)
The Chart of the Day is Seattle Genetics (SGEN) and was found by sorting the Barchart New High list for
frequency then using the Flipchart function to review the charts. In
the last month the stock rose in 17 session for a gain of 29.63% and has
a Trend Spotter buy signal. It has great fundamentals for next year.
The Company develops monoclonal antibody-based drugs to treat cancer and related diseases. Using its monoclonal antibody-based technologies and its expertise in cancer, they have assembled a portfolio of drug candidates targeted to many types of human cancers.
Please share this article
The Company develops monoclonal antibody-based drugs to treat cancer and related diseases. Using its monoclonal antibody-based technologies and its expertise in cancer, they have assembled a portfolio of drug candidates targeted to many types of human cancers.
Please share this article
Subscribe to:
Posts (Atom)